Clinical Trials
26 trialsAMEERA-1
Sanofi
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
NiKang Therapeutics, Inc.
WI223281
Georgetown University
AMEERA-5
Sanofi
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
Tvardi Therapeutics, Incorporated
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
M.D. Anderson Cancer Center
IPATunity150
Hoffmann-La Roche
Palbociclib + Ganitumab In Ewing Sarcoma
Dana-Farber Cancer Institute
PASIPHAE
Karolinska University Hospital
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
University of Kansas Medical Center
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
SPRING
Worldwide Innovative Network Association
Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
TAILOR
Peter MacCallum Cancer Centre, Australia
Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
Jonsson Comprehensive Cancer Center
PRECYCLE
Palleos Healthcare GmbH
PALTAN
Washington University School of Medicine
A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
Genentech, Inc.
Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)
Pfizer
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Pediatric Brain Tumor Consortium
Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis
Northwestern University
Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma
Weill Medical College of Cornell University
Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy
UNC Lineberger Comprehensive Cancer Center
PD + RD
Weill Medical College of Cornell University
PD0332991
University of California, San Francisco